2017 Medicare Part-D Plans in Puerto Rico
There are 6 Medicare Part-D Plans available in Puerto Rico from 4 different health insurance providers. You can choose from 1 prescription drug plans offering additional gap coverage. The plan with the lowest monthly premium is $12 and the highest monthly premium is $74. The highest rated PDP available in Puerto Rico County received a 4 overall star rating from the CMS and the lowest rated plan is 3 stars.
(Click the Plan Name for More Details)
|AARP MedicareRx Preferred (PDP)
|$55.30||$400.00||Basic||No||No||See The |
|$62.70||$400.00||Basic||No||No||See The |
|Express Scripts Medicare - Choice (PDP)
|$74.50||$350.00||Enhanced||No||No||See The |
|Express Scripts Medicare - Value (PDP)
|$53.10||$400.00||Basic||No||No||See The |
|Humana Enhanced (PDP)
|$47.30||$0.00||Enhanced||Yes||No||See The |
|Humana Preferred Rx Plan (PDP)
|$12.90||$400.00||Basic||No||No||See The |
|Return 2017 Medicare Part D Plans|
|2017 Medicare Advantage in Puerto Rico|
Enhanced Alternative plans may offer additional gap coverage which is calculated as the percentage of generic formulary products with coverage above standard "generic" coverage gap cost-sharing benefit and/or the percentage of brand formulary products covered in addition to the coverage gap discount for applicable drugs.GAP
In 2017 once you and your plan provider have spent $3700 on covered drugs. (combined amount plus your deductible) You will be in the coverage gap. (AKA "donut hole") Once you reach the coverage gap you will pay 40% of the plans cost for covered brand-name prescription drugs and 51% on generic drugs unless your plan offers additional coverage. You will still receive a 60% discount on brand-name drugs and a 49% discount on generic drugs.
Plans as of September 6, 2016.
Plans are subject to change as contracts are finalized.
Includes 2017 approved contracts/plans. Employer sponsored 800 series plans and plans under sanction are excluded. For 2017, enhanced alternative plans may offer additional cost sharing reductions in the gap on a sub-set of the formulary drugs, beyond the standard Part D benefit.